Skip to content

MDMA research published in 2026

Page 4 of 8: studies 61 to 80 of 151, newest first. Back to the MDMA overview

Studies

Semi-Quantitative Estimation of MDMA Tablet Dosage and Cocaine/Ketamine Purity Using a Simple to Operate Field-Portable Device

ChemRxiv June 9, 2026 Matthew Gardner, Alexander Power, Anca Frinculescu et al. preprint

High-dose MDMA tablets and variable-purity cocaine and ketamine samples are commonly encountered by drug checking services and police forces in the United Kingdom and Europe. At the time of writing, there are few simpleto-operate field-portable technologies that provide semi-quantitative information on MDMA tablet dosage or cocaine and ketamine purity at the point of sampling. We previously...

Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis

Psychoactives June 8, 2026 Fizza Mitter, Anton Sheptooha, Janni Leung et al.

Post-traumatic stress disorder (PTSD) remains inadequately treated by existing pharmacological and psychological interventions, prompting growing interest in psychedelic-assisted psychotherapy. Although randomised controlled trials have evaluated several psychedelic agents for PTSD, to our knowledge, no prior PTSD-specific synthesis has quantitatively examined multiple agent classes within a...

DOI: 10.3390/psychoactives5020016 (opens in new tab) MDMA Cannabidiol Systematic review Randomized controlled trial +7

Understanding How Trait Negative Emotionality (NEM) Influences Social Connectedness and Responses to ± 3,4-Methylenedioxymethamphetamine (MDMA)

University of Chicago June 6, 2026 Ruiyan Hu

Negative Emotionality (NEM) is a trait measure that reflects a tendency toward experiencing intense negative emotions and heightened reactivity to perceived threats or stressors, contributing to challenges with social integration and interpersonal relationships. This secondary analysis in healthy volunteers (N = 30) employed a within-subject, double-blind, placebo-controlled design to...

DOI: 10.6082/2hxmy-m0z74 (opens in new tab) Trait Social connectedness Personality Population +9

The Role of the Basolateral and Central Amygdala During Heroin Withdrawal and 3,4-Methylenedioxymethamphetamine Administration

UNC Libraries June 5, 2026 Charlotte Rubin

Opioid use disorder (OUD) is characterized by dependence, withdrawal, and high relapse risk, yet the neuroimmune mechanisms underlying withdrawal in the amygdala remain poorly understood. This study investigated whether 3,4-methylenedioxymethamphetamine (MDMA) modulates heroin withdrawal–induced neuroinflammation in the central amygdala (CeA) and basolateral amygdala (BLA). Adult male...

DOI: 10.17615/32dy-yq54 (opens in new tab) MDMA Heroin Basolateral amygdala Cytokine +6

Happy water overdose: A trending but fatal street drug

Myanmar Medical Journal June 4, 2026 Aung Kyaw Thu, Zaw Hlaing Toe, Si Thu Linn

“Happy water” has been gaining popularity among party goers. The effect of consuming this drug can be fatal. Two patients of “Happy water” overdose were admitted for reduced level of consciousness after enjoying a farewell party at nightclub. Urine for toxicology screening was found to be positive for methylenedioxymethamphetamine (MDMA), methamphetamine, diazepam and tramadol. “Happy water” is...

MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial

June 4, 2026 Jason B. Luoma, M. Kati Lear, Brian Pilecki et al. preprint

Background: ±3,4-methylenedioxymethamphetamine (MDMA) has positive effects on socio-emotional processing and MDMA-Assisted Therapy (MDMA-AT) showed promise for treating SAD in a previous placebo-controlled trial. Aims: Develop a preliminary estimate of clinical response and safety for MDMA-AT versus waitlist in adults with SAD. Secondary aims included refinement of a standardized psychotherapy...

DOI: 10.31234/osf.io/a9x6d_v1 (opens in new tab) Social anxiety Randomized controlled trial Adverse effect Clinical trial +3

Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study

Translational Psychiatry June 4, 2026 Mélusine Humbert‐droz, Anna M Becker, Jan Valenta et al.

3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is being investigated as a treatment for several psychiatric disorders, particularly posttraumatic stress disorder. Phase 2 and 3 trials typically administered a first dose of MDMA followed by a second "booster" dose 1.5-2.5 h later, to extend the acute effect duration. However, the risks and benefits of the booster dose...

MDMA-Assisted Psychotherapy for Cluster B Personality Disorders: A Narrative Review of This Translational Framework for Relational Healing

European Psychiatry June 1, 2026 M. Rocha, V. Sharma, S. Prasad et al.

Introduction Psychedelic-assisted psychotherapy has re-emerged as a frontier of psychiatry, offering transformative potential for conditions resistant to conventional treatment. Personality disorders—particularly Borderline Personality Disorder (BPD)—are marked by affective instability, interpersonal dysfunction, and maladaptive relational patterns that often limit therapeutic progress. MDMA’s...

DOI: 10.1192/j.eurpsy.2026.11914 (opens in new tab) Full text (opens in new tab) Borderline personality disorder Openness to experience Interpersonal communication Narrative review +13

Exploring Attitudes Toward MDMA-Assisted Therapy in Mental Health Care

European Psychiatry June 1, 2026 Agnieszka Mechlińska, Damian Swieczkowski, Aleksander Kwaśny et al.

Introduction MDMA (3,4-methylenedioxymethamphetamine)–assisted therapy has gained growing scientific attention as a potential treatment for post-traumatic stress disorder and other mental health conditions. Although clinical studies suggest potential benefits, concerns remain regarding cardiovascular safety, methodological rigor, and variability in psychotherapeutic support (Singh et al . CNS...

Synthetic Drugs and Behavioural Addictions: LSD, MDMA and Digital Toxicity

June 1, 2026 Sharda More-Pol

The emergence of contemporary psychological stressors, synthetic psychoactive substance abuse, and non-substance behavioral dependency networks presents critical investigative challenges within public healthcare and classical toxicology (Agadatantra), traditionally analyzed through the concepts of Madya (intoxicants), Mada (intoxication), and severe cognitive perversion (Prajñāparādha). This...

Monday mood decline after weekend ecstasy use: A retrospective analysis of daily diary reports.

Drug and Alcohol Dependence Reports June 1, 2026 Christopher Medina-Kirchner, Scott E Lukas

Ecstasy is commonly used on weekends and linked to post-use mood declines. Laboratory studies with pure MDMA rarely detect residual effects, whereas naturalistic studies more often report mood reductions. The timing and contextual drivers of these effects remain unclear. Data from seventeen participants reporting weekend ecstasy use (10 male, 7 female; 19-38 years) were drawn from a previously...

From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder.

Journal of Traumatic Stress June 1, 2026 Kadek Suhardita, Veno Dwi Krisnanda, Rikas Saputra et al.

In this commentary on Morland et al. (2026)'s recent State of the Science article on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD), we aim to emphasize both MDMA's therapeutic promise and its unresolved scientific challenges. Although recent trials on MDMA-assisted interventions have reported encouraging reductions in PTSD symptoms, the...

Antibiotic-induced Microbiome Depletion Selectively Reduces Baseline Hypothalamic Oxytocin Signaling without Affecting MDMA-induced Oxytocin Response in Rats.

Clinical Psychopharmacology and Neuroscience May 31, 2026 Yong Yue, Yi Cai, Rumi Murayama et al.

To determine whether antibiotic-induced microbiome depletion influences baseline or 3,4-methylenedioxymethamphetamine (MDMA)-induced oxytocin signaling in rats. Male Wistar rats received broad-spectrum antibiotics (ABX) or water for 7 days, followed by a single oral administration of MDMA (30 mg/kg). Plasma oxytocin levels were measured by ELISA, and oxytocin-immunoreactivity in the...

DOI: 10.9758/cpn.25.1381 (opens in new tab) Full text (opens in new tab) Anti-bacterial agents Gut-brain axis N-methyl-3,4-methylenedioxyamphetamine Oxytocin

The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology & Therapeutics May 28, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al.

Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor-level treatment strategies beyond monoamine reuptake. The serotonin 5-HT2B receptor (5-HT2BR) is uniquely positioned at the interface of central-antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and...

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.

European Neuropsychopharmacology May 28, 2026 L Belinger, Nathalie M. Rieser, Etna Engeli et al.

Maintaining effective blinding is a major methodological challenge in psychedelic research. This study provides a comprehensive evaluation of blinding integrity in 120 healthy volunteers who received either psilocybin, MDMA, or methylphenidate (active placebo) in a double-blind, randomized controlled trial. Using a multi-level assessment incorporating forced-choice substance guesses, certainty...

Symbols of Mystical Ecstasy and Divine Love in the Poetry of ’A’ishah al-Ba’uniyya and W.B. Yeats: A Heideggerian Re-interpretation

Maǧallaẗ Kulliyyaẗ Al-Adāb - Ǧāmiʿaẗ Al-Fayūm May 25, 2026 Gehan Anwar Deep

Ecstasy, though, is an inexpressible and condensed experience through which the Ultimate can be revealed, the mystic poet finds expression in resorting to symbolism to reflect the uniqueness of his/her spiritual experience and to communicate the unsaying. Approaching the divine essence and expressing the euphoria of His presence in meditation, recollection and self-forgetfulness are often...

DOI: 10.21608/jfafu.2021.78386.1530 (opens in new tab) Full text (opens in new tab) Symbolic poetry Al-ba'uniyyah and yeats Jung's individuation

Vision Through Ecstasy: Fabián Cháirez & Queer Catholic Symbology

Ekphrasis: An Art History Graduate Journal May 22, 2026 Maya Cristina Ramirez

Spanish colonialism in the Americas offered a single vision of holiness, crafting Western notions of visuality and sign(s) as rooted in Christian imagery. The reality of figures of faith is bound to images and visual perception. This paper aims to examine this notion, how it upholds Western power structures, and how mysticism disrupts gendered boundaries within the Catholic Church. Mystic...

Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms.

Translational Psychiatry May 21, 2026 Francesco Bavato, Andrea E. Steuer, Anna M. Jacobsen et al.

Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are two types of substituted amphetamines that share structural-chemical similarities but exhibit contrasting acute and chronic effects including addictive liability. Tryptophan (TRY) pathways are involved in pleiotropic physiological functions at the interface of brain-body connections. Preclinical...